Abdul Sankari, MD
Cardiovascular Disease · New Lenox, ILNPI 1326097239
Payments from drug & device makers
Across 201 payments — averaging $48.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Medtronic$1K
- Boston Scientific$666
- AOP Health US, LLC$407
- Pfizer$357
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$2,25023%
- Travel & lodging$3,09232%
- Food & beverage$4,30445%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $2,580 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $2,554 |
| Medtronic(2 entities) | 13 | $1,254 |
| Boston Scientific | 9 | $666 |
| AOP Health US, LLC | 1 | $407 |
| Pfizer | 24 | $357 |
| Novartis | 20 | $292 |
| Boehringer Ingelheim | 11 | $229 |
| Johnson & Johnson | 18 | $226 |
| AstraZeneca | 10 | $173 |
| Amarin Pharma, Inc. | 10 | $137 |
| Merck | 9 | $131 |
| E.r. Squibb & Sons, L.L.C. | 8 | $120 |
| Amgen | 7 | $96 |
| Sanofi-aventis U.S. LLC | 6 | $94 |
| Chiesi USA, Inc. | 3 | $55 |
| Novo Nordisk | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Portola Pharmaceuticals, LLC | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Cook Medical LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Teleflex LLC | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
| Penumbra, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$2,250
- Xience V coronary stent system$1,923
- IN.PACT Admiral$930
- Rapiblyk$814
- GENERAL VASCULAR ACCESS$481
- AVEIR$100
How this compares
$9,660 in reported general payments places this provider in the 75th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 559 | $751,281 |
| EntrestoSacubitril/Valsartan | 275 | $357,959 |
| XareltoRivaroxaban | 184 | $215,082 |
| BrilintaTicagrelor | 91 | $80,140 |
| Repatha SureclickEvolocumab | 63 | $71,367 |
| JardianceEmpagliflozin | 41 | $39,851 |
| FarxigaDapagliflozin Propanediol | 25 | $23,040 |
| MultaqDronedarone Hcl | 15 | $18,931 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $14,289 |
| Atorvastatin Calcium | 1,036 | $11,279 |
| Metoprolol Succinate | 676 | $10,513 |
| NexletolBempedoic Acid | 15 | $9,052 |
| Ranolazine ErRanolazine | 42 | $8,641 |
| Carvedilol | 776 | $8,382 |
| ClopidogrelClopidogrel Bisulfate | 548 | $6,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $357 | $751,281559 claims |
| NovartisEntresto | $292 | $357,959275 claims |
| Johnson & JohnsonXarelto | $226 | $215,082184 claims |
| AstraZenecaBrilinta, Farxiga | $173 | $103,181116 claims |
| Boehringer IngelheimJardiance | $229 | $39,85141 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $33 | $23,34134 claims |
| Sanofi-aventis U.S. LLCMultaq | $94 | $18,93115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in New Lenox
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.